Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

Stock Information for Hemostemix

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Hemostemix

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.